Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy for heart failure, with an initial focus on pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). On a conference call led by Martin Brenner and Cory […]